Relationship between Sakita endoscopic stage and duration of treatment for duodenal XXXX .

@entity4444 @entity1 @entity1066
1. Endoscopic staging of peptic @entity1066 lesions according to Sakita will be a methodological improvement in therapeutic trials provided that the correlation between stages and the time spent in treatment is proved valid. 2. We describe a double-blind controlled randomized trial carried out to determine the efficacy of @entity4444 in @entity1 with duodenal @entity1066 in the H stage of Sakita endoscopic staging. Fifty-two @entity1 with duodenal @entity1066 (H stage) were randomly allocated to receive either 400 mg @entity4444 twice daily (N = 26), or placebo (N = 26) for two weeks; @entity1 with unhealed ulcers continued the same treatment for an additional week. 3. Of the @entity4444 -treated @entity1 , 19 (73%) were healed after two weeks and 23 (88.5%) after three weeks of treatment, and of the placebo-treated @entity1 , 8 (31%) were healed after two and 13 (50%) after three weeks. 4. These differences indicate a natural tendency of the H stage lesions to heal faster than reported for the active (stage A) lesions and still faster if treated with @entity4444 . These findings, by establishing a relationship between the @entity1066 stage and the time spent in treatment, may help the physician to treat duodenal @entity1066 @entity1 and will enable the adoption of an important, uniform criterion for selection of duodenal @entity1066 @entity1 for therapeutic trials, especially in multicenter trials.
